PIPGEN - PhD Project 8: The role of PI3Kdelta in solid tumours and its modulation using novel pharmacological tools.
Research · University College of London (UCL)>UK
RESEARCH PROFILE: First Stage Researcher (R1)
APPLICATION DEADLINE: 27 June 2021
EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020
MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534
 First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.
PhD Project details
There is emerging evidence for a cancer-cell-intrinsic role of PI3Kdelta in solid tumours, but this has not been formally proven. ESR8 will investigate the role and mechanism of action of cancer-cell-intrinsic PI3Kdelta in solid tumours, and its importance in responsiveness to novel pharmacological tools that modulate PI3Kdelta activity (such as IOA-244 from iOnctura and others). The focus will be on cell types expressing high levels of PI3Kdelta, including glioblastoma and melanoma, with some studies on specific lymphoma subtypes. ESR8 will perform CRISPR-out the PI3Kdelta gene from selected tumour cell lines to investigate the impact in cancer-relevant biology in vitro and in vivo, using advanced signalling studies by proteomic and genomic analyses (such as RNAseq, epigenetics) and cell biology.
Host: University College of London, UK.
Supervisor: Prof Bart Vanhaesebroeck.
Doctoral programme: University College of London.
Envisioned secondments: iOnctura, UCAM.
To apply for the UCL positions, in addition to the procedures outlined here, a further application will need to be completed via the UCL website – this is to conform with UCL’s own recruitment process. This second step is not yet available online, but we will inform candidates as soon as it opens.